Intracoronary tirofiban
PreclinicalSmall molecule
Intracoronary tirofiban is one of 6 small molecule programs targeting STEMI. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
5 competitors in STEMI
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Repatha
UUniversity of California, Los Angeles
Phase 3
Calciparine
BBaxter Healthcare Corporation
Preclinical
Unfractionated Heparin
GSKPreclinical
Intracoronary tirofiban
KKafrelsheikh University
Preclinical
Β -Blockers
QQilu Hospital of Shandong University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intracoronary tirofiban. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- KKafrelsheikh University